Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.82 is 179% above its 5-year average of 4.60, near the high end of its 5-year range (2.62–14.02).
As of the fiscal period ended Tuesday, June 30, 2026. 31.41% above its 12-month average of 9.76.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.82.
CURRENT RATIO
12.82
CURRENT RATIO AVG TTM
9.76
CURRENT RATIO AVG 3Y
6.80
CURRENT RATIO AVG 5Y
4.60
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+31.41%
CURRENT VS 3Y AVG
+88.55%
CURRENT VS 5Y AVG
+178.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 506 covered companies
CURRENT VS SECTOR MEDIAN
+282.18%
vs the sector median at left
Precision BioSciences, Inc.
Market Cap
$174.17M
Current Ratio
12.82
TTM Avg
9.76
3Y Avg
6.80
5Y Avg
4.60
Market Cap
$172.99M
Current Ratio
11.22
TTM Avg
14.99
3Y Avg
15.44
5Y Avg
13.43
Market Cap
$179.70M
Current Ratio
15.70
TTM Avg
3.42
3Y Avg
4.67
5Y Avg
3.16
Market Cap
$184.12M
Current Ratio
1.59
TTM Avg
1.58
3Y Avg
1.42
5Y Avg
1.43
Market Cap
$160.13M
Current Ratio
9.71
TTM Avg
4.67
3Y Avg
6.04
5Y Avg
19.74
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $174.17M | 12.82 | 9.76 | 6.80 | 4.60 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | 1.77 | 1.33 | 1.71 | 2.63 |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | 11.22 | 14.99 | 15.44 | 13.43 |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | 1.25 | 2.29 | 3.57 | 4.16 |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | 15.70 | 3.42 | 4.67 | 3.16 |
| Journey Medical Corporation (DERM)vs › | $184.12M | 1.59 | 1.58 | 1.42 | 1.43 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $160.13M | 9.71 | 4.67 | 6.04 | 19.74 |
| Inogen, Inc. (INGN)vs › | $160.82M | 2.74 | 2.77 | 3.26 | 3.97 |
| LifeMD, Inc. (LFMDP)vs › | $155.88M | 0.90 | 1.03 | 0.91 | 1.08 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | 7.90 | 9.91 | 10.86 | 18.34 |
Current Ratio
12.82
Quick Ratio
12.82
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.82 |
| 2026-03-31 | 14.02 |
| 2025-12-31 | 13.32 |
| 2025-09-30 | 3.45 |
| 2025-06-30 | 5.18 |
| 2025-03-31 | 6.62 |
| 2024-12-31 | 6.34 |
| 2024-09-30 | 9.22 |
| 2024-06-30 | 4.37 |
| 2024-03-31 | 4.82 |
| 2023-12-31 | 2.73 |
| 2023-09-30 | 2.88 |
| 2023-06-30 | 2.62 |
| 2023-03-31 | 3.61 |
| 2022-12-31 | 3.34 |
| 2022-09-30 | 3.69 |
| 2022-06-30 | 4.59 |
| 2022-03-31 | 4.61 |
| 2021-12-31 | 4.50 |
| 2021-09-30 | 5.02 |
| 2021-06-30 | 5.19 |
| 2021-03-31 | 3.43 |
| 2020-12-31 | 2.46 |
| 2020-09-30 | 2.92 |
| 2020-06-30 | 4.00 |
| 2020-03-31 | 7.02 |
| 2019-12-31 | 7.19 |
| 2019-09-30 | 9.25 |
| 2019-06-30 | 14.99 |
| 2019-03-31 | 1.92 |
| 2018-12-31 | 8.22 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
